Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Archive of News

<< 2010 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2012 >>

7 December 2011: Partnership with Cisco & Imperial in Tech City

London has moved a step closer towards becoming a global leader in future cities research after UCL, Imperial College London and Cisco entered into a three year initial agreement to create a Future Cities Centre in the capital.
More...

<< 2010 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2012 >>